From clinical trials, the researchers also knew that non-small cell lung cancers in people with a sensitive EGFR mutation were very responsive to gefitinib, but little was known about the medication's safety profile or effectiveness compared with standard chemotherapy. 研究人员从临床试验得知也知道在患非小细胞肺癌是并具有EGFR突变的患者，对吉非替尼非常敏感并且有反应。但关于药物的安全性或者有效性相对于标准化疗的效果却知之甚少。
For this reason, Dr. Akira Inoue and his colleagues focused on 230 patients with the EGFR mutation and metastatic non-small-cell lung cancer; the patients were treated in 43 different medical facilities between 2006 and 2009 throughout Japan. In a randomized case-control study, half were given gefitinib, while the others received standard chemotherapy. 因为以上的原因，明井上博士和他的同事们重点放在转移性非小细胞肺癌 EGFR 突变的 230 患者；在 2006 年至2009年，在日本对这些病人实施了 43 种不同治疗施。随机的病例对照研究，一半用吉非替尼，而其他人用标准化疗。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
